NCT06446206View on ClinicalTrials.gov

Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2028

Conditions
Platinum-sensitive Relapsed Ovarian Cancer
Interventions
DRUG

Adebrelimab, paclitaxel, carboplatin, bevacizumab, fluzoparib

Adebrelimab plus paclitaxel, carboplatin and bevacizumab induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib and bevacizumab.

All Listed Sponsors
lead

The First Hospital of Jilin University

OTHER

NCT06446206 - Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian Cancer | Biotech Hunter | Biotech Hunter